[Inhibitory effect of anluohuaxianwan on experimental hepatic fibrosis in rats].
OBJECTIVE
To investigate the effects of anluohuaqianwan on experimental hepatic fibrosis induced by dimethyl nitrosamine (DMN) in rats.


METHODS
36 male SD rats were randomly dividied into three groups: model group, normal group, anluohuaqianwan group. The rats in the three groups were treated with DMN daily for 4 weeks. The liver function was detected using auto biochemistry analyzer, the serum HA, LN, IV-C, PIIIP were detected by immunoradiometry, the histopathology was observed in the left liver lobe after HE staining, the expression of matrix metalloproteinase-2 (MMP-2) in liver tissue were detected by immunohistochemistry.


RESULTS
The serum levels of ALT, AST, ALP, TP, ALB and the contents of HA, LN, IV-C in model group were significantly increased compared to these in the normal group (P less than 0.01). The serum levels of ALT, AST and the contents of HA in anluohuaqianwan group were significantly lower than those in the model group (P less than 0.01). The liver MMP-2 in the model group was significantly increased compared to that in the normal group (P less than 0.05). The expression of MMP-2 in liver tissue of model group was lower than that in the anluohuaqianwan group (P less than 0.05).


CONCLUSIONS
Anluohuaqianwan can inhibit liver fibrosis in rats induced by DMN.
Tan
Xing-Hua
XH
Department of Liver Diseases, the Eighth People's Hospital of Guangzhou, Guangzhou 510060,China.
Li
Chang-Qing
CQ
Zou
Shang-Rong
SR
Xie
Min
M
Zhang
Ai-Min
AM
Li
Wen-Li
WL
Li
Xiao-Yue
XY
Huang
Hui-Fen
HF
Lei
Chun-Liang
CL
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D004128:Dimethylnitrosamine; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D006820:Hyaluronic Acid / Q000097:blood*; D006909:Hydroxyproline / Q000378:metabolism; D007150:Immunohistochemistry; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D006820:Hyaluronic Acid; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D020778:Matrix Metalloproteinase 2; C522363:Mmp2 protein, rat; D004128:Dimethylnitrosamine; D006909:Hydroxyproline